You just read:

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

News provided by

Rigel Pharmaceuticals, Inc.

Oct 11, 2018, 07:30 ET